Chasing Mylan, Hikma tries again with rejected generic Advair in USUK-listed Hikma Pharma has filed a response to the FDA that it hopes will clear the way for Share XChasing Mylan, Hikma tries again with rejected generic Advair in UShttps://pharmaphorum.com/news/chasing-mylan-hikma-tries-again-with-rejected-generic-advair-in-us/
Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
Shingles vaccine boosts GSK as generic Advair bitesGSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of Share XShingles vaccine boosts GSK as generic Advair biteshttps://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/
Advair reprieve gives GSK breathing spaceGlaxoSmithKline looks set to have another year without US generic competition to its respiratory blockbuster Advair, after the Share XAdvair reprieve gives GSK breathing spacehttps://pharmaphorum.com/news/advair-reprieve-gives-gsk-breathing-space/
GSK’s new pharma chief Miels to join in SeptemberLuke Miels to start role after GSK and AZ end contract row. Share XGSK’s new pharma chief Miels to join in Septemberhttps://pharmaphorum.com/news/gsks-new-pharma-chief-join-september/